R. Salem, A. C. Gordon, S. Mouli, R. Hickey, J. Kallini et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology. déc, vol.151, issue.6, pp.1155-1163, 2016.

J. Edeline, L. Crouzet, B. Campillo-gimenez, Y. Rolland, M. Pracht et al., Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis, Eur J Nucl Med Mol Imaging. avr, vol.43, issue.4, pp.635-678, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01217979

A. B. El-khoueiry, B. Sangro, T. Yau, T. S. Crocenzi, M. Kudo et al., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, noncomparative, phase 1/2 dose escalation and expansion trial. The Lancet, vol.389, pp.2492-502, 2017.

A. X. Zhu, R. S. Finn, E. J. Cattan, S. Ogasawara, S. Palmer et al., Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol. juill, vol.19, issue.7, pp.940-52, 2018.

A. Cheng, S. Qin, M. Ikeda, P. Galle, M. Ducreux et al., LBA3 -IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC), Annals of Oncology, vol.30, pp.186-193, 2019.

A. J. Templeton, M. G. Mcnamara, B. Eruga, F. E. Vera-badillo, P. Aneja et al., Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis, JNCI Journal of the National Cancer Institute. 29 mai, vol.106, issue.6, pp.124-124, 2014.

N. Nakamura, Y. Kusunoki, and M. Akiyama, Radiosensitivity of CD4 or CD8 positive human Tlymphocytes by an in vitro colony formation assay, Radiat Res. août, vol.123, issue.2, pp.224-231, 1990.

Q. Zhao, X. Xu, J. Yue, K. Zhu, R. Feng et al., Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma, Therap Adv Gastroenterol. févr, vol.10, issue.2, pp.231-272, 2017.

A. Domouchtsidou, V. Barsegian, S. P. Mueller, J. Best, J. Ertle et al., Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy, Cancer Immunol Immunother. mai, vol.67, issue.5, pp.843-53, 2018.

V. Chew, Y. H. Lee, L. Pan, N. Nasir, C. J. Lim et al., Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma, Gut. févr, vol.68, issue.2, pp.335-381, 2019.

T. F. Greten, M. Mauda-havakuk, B. Heinrich, F. Korangy, and B. J. Wood, Combined locoregionalimmunotherapy for liver cancer, J Hepatol. mai, vol.70, issue.5, pp.999-1007, 2019.

S. C. Formenti and S. Demaria, Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift, JNCI Journal of the National Cancer Institute. 20 févr, vol.105, issue.4, pp.256-65, 2013.

R. Salem, R. J. Lewandowski, V. L. Gates, C. W. Nutting, R. Murthy et al., Research reporting standards for radioembolization of hepatic malignancies, J Vasc Interv Radiol. mars, vol.22, issue.3, pp.265-78, 2011.

E. Garin, L. Lenoir, E. J. Laffont, S. Mesbah, H. Porée et al., Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept, Eur J Nucl Med Mol Imaging. juill, vol.40, issue.7, pp.1057-68, 2013.

E. Garin, Y. Rolland, E. J. Icard, N. Lenoir, L. Laffont et al., Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med. mars, vol.56, issue.3, pp.339-385, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01128116

R. Avritscher, J. N. Polak, U. Cortes, A. C. Nishiofuku, H. Odisio et al., Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma, Cardiovasc Intervent Radiol, 2019.

M. Seidensticker, M. Powerski, R. Seidensticker, R. Damm, K. Mohnike et al., Cytokines and (90)Y-Radioembolization: Relation to Liver Function and Overall Survival, Cardiovasc Intervent Radiol. août, vol.40, issue.8, pp.1185-95, 2017.

C. Chiesa, M. Mira, M. Maccauro, R. Romito, C. Spreafico et al., A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres, Q J Nucl Med Mol Imaging. déc, vol.56, issue.6, pp.503-511, 2012.

F. Bigot, E. Castanon, C. Baldini, A. Hollebecque, A. Carmona et al., Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score), Eur J Cancer, vol.84, pp.212-220, 2017.

M. Capone, D. Giannarelli, D. Mallardo, G. Madonna, L. Festino et al., Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab, J Immunother Cancer. 16 juill, vol.6, issue.1, p.74, 2018.